Coenzyme Q10 reduction with statins: Another pleiotropic effect

Current Drug Therapy

Volumn 2, Issue 1, 2007, Pages 39-51

  Mabuchi, Hiroshi ^a   Nohara, Atsusi ^a   Kobayashi, Junji ^a   Kawashiri, Masa Aki ^b   Inazu, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Department of Molecular Genetics of Cardiovascular Disorders ^*

Author keywords

CoQ10; Mevalonate pathway; Pleiotropic effect; Rhabdomyolysis; Squalene synthase inhibitor; Statin

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; [5 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO] 1,3,4 THIADIAZOL 2 YLTHIO]ACETIC ACID; ANTIOXIDANT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; ER 27856; FIBRIC ACID DERIVATIVE; FR 194738; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; LIPOPROTEIN; MEVALONATE KINASE; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; RPR 107393; SIMVASTATIN; SQUALENE MONOOXYGENASE INHIBITOR; SQUALENE SYNTHASE INHIBITOR; SQUALESTATIN; TAK 475; TRIPARANOL; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 53546; YM 53601;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CATARACT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALOMYOPATHY; ENZYME DEFICIENCY; ENZYME INHIBITION; EPIDEMIOLOGICAL DATA; HAIR LOSS; HUMAN; HYPERCHOLESTEROLEMIA; ICHTHYOSIS; ISCHEMIC HEART DISEASE; LIPOPHILICITY; LIVER DYSFUNCTION; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; MYOPATHY; NONHUMAN; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SECONDARY PREVENTION;

EID: 34248214318     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488507779422338     Document Type: Review

References (134)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
5. Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004; 350: 1562-4.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-82.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
9. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
10. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
11. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347: 102-3.
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
13. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86: 5-18.
14. Gotto AM Jr, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12: 391-4
15. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24: 225-48.
16. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005; 111: 2280-1.
17. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207
18. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
19. Hawk E, Viner JL. Statins and cancer-beyond the "one drug, one disease" model. N Engl J Med 2005; 352: 2238-9.
20. Kivipelto M, Solomon A, Winblad B. Statin therapy in Alzheimer's disease. Lancet Neurol 2005; 4: 521-2.
21. Coons JC. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 2002; 36: 326-30.
22. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
23. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
24. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109 (Suppl 1): III50-7.
25. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-8.
26. Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111: 3016-9.
27. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003; 18: 101-11.
28. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91: 4B-8B.
29. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505-17.
30. Faust JR, Goldstein JL, Brown MS. Synthesis of ubiquinone and cholesterol in human fibroblasts: regulation of a branched pathway. Arch Biochem Biophys 1979; 192: 86-99.
31. Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med 1981; 305: 478-82.
32. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 1957; 25: 220-1.
33. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20: 591-8.
34. Ernster L, Forsmark-Andree P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 1993; 71(8 Suppl): S60-5.
35. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 1997; 250: 66-73
36. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
37. Hoffmann G, Gibson KM, Brandt IK, Bader PI, Wappner RS, Sweetman L. Mevalonic aciduria - an inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med 1986; 314: 1610-4.
38. Hubner C, Hoffmann GF, Charpentier C, et al. Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr Res 1993; 34: 129-33.
39. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348: 2656-68.
40. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989; 86: 2379-82.
41. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care 2005; 8: 641-6.
42. Folkers K, Littarru GP, Ho L, Runge TM, Havanonda. S, Cooley D. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch 1970; 40: 380-90.
43. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 901-4.
44. Hanaki Y, Sugiyama S, Ozawa T, Ohno M. Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factor. N Engl J Med 1991; 325: 814-5.
45. Hanaki Y, Sugiyama S, Ozawa T, Ohno M. Coenzyme Q10 and coronary artery disease. Clin Investig 1993; 71(8 Suppl): S112-5.
46. Kontush A, Reich A, Baum K, et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis 1997; 129: 119-26.
47. Thomas SR, Witting PK, Stocker R. A role for reduced coenzyme Q in atherosclerosis? Biofactors 1999; 9: 207-24.
48. Hargreaves IP. Ubiquinone: cholesterol's reclusive cousin. Ann Clin Biochem 2003; 40: 207-18.
49. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone- 10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005; 12: 111-9.
50. Elmberger PG, Kalen A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991; 32: 935-40.
51. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204.
52. Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004; 194: 10-23.
53. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-4.
54. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
55. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005; 13: 76-9.
56. Blohm TR, Mackenzie RD. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys 1959; 85: 245-9.
57. Laughlin RC, Carey TF. Cataracts in patients treated with triparanol. JAMA 1962; 181: 339-40.
58. Shen W, Garvey DS, Cohen J, Stein H, Rosenberg SH. Cyclopentanedi-and tricarboxylic acids as squalene synthase inhibitors: syntheses and evaluation. Bioorg Med Chem Lett 1998; 8: 891-6.
59. Amin D, Rutledge RZ, Needle SN, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997; 281: 746-52.
60. Baxter A, Fitzgerald BJ, Hutson JL, et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers senun cholesterol in vivo. J Biol Chem 1992; 267: 11705-8.
61. Piper E, Price G, Chen Y. TAK-475, a squalene synthase inhibitor, improves lipid profiles in hyperlipidemic subjects. American Heart Association Scientific Sessions 2006. Abstract 1493.
62. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Ther 1998; 15: 218-228.
63. Chugh A, Ray A, Gupta JB. Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res 2003; 42: 37-50.
64. Horie M, Sawasaki Y, Fukuzumi H, et al. Hypolipidemic effects of NB-598 in dogs. Atherosclerosis 1991; 88: 183-92.
65. Sawada M, Washizuka K, Okumura H. Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett 2004; 14: 633-7.
66. Watanabe S, Hirai H, Kambara T, et al. CJ-13,981 and CJ-13,982, new squalene synthase inhibitors. J Antibiot (Tokyo) 2001; 54: 1025-30.
67. Nishimoto T, Amano Y, Tozawa R, et al. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 2003; 139: 911-8.
68. Nishimoto T, Tozawa F. Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003; 66: 2133-9.
69. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-5.
70. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108(7): 839-43.
71. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
72. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004; 36: 1539-41.
73. Stojanovic I, Vrtovec B, Radovancevic B, et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up. J Heart Lung Transplant 2005; 24: 1235-8.
74. Wenke K, Meiser B, Thiery J, Reichart B. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz 2005; 30: 431-2.
75. Wu AH, Ballantyne CK Short BC, et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol 2005; 95: 367-72.
76. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-63.
77. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-97.
78. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716-23.
79. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
80. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-7.
81. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-8.
82. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
83. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-8.
84. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-7.
85. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62: 1047:51.
86. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003; 12: 607-11.
87. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10.
88. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-8.
89. Coons JC. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 2002; 36: 326-30.
90. LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139: 97-104.
91. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-9.
92. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66: 1549-55.
93. Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant 2004; 19: 2378-86.
94. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-70.
95. Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-45.
96. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52-60.
97. Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-13.
98. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med Wochenschr 1998; 128: 272-7.
99. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-7.
100. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002; 40: 67-73.
101. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-8.
102. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931-4.
103. Watts GF, Castelluccio, C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 1993; 46: 1055-7.
104. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226-9.
105. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994; 24: 171-6.
106. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46: 313-7.
107. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57: 62-6.
108. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333-7.
109. Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997; 263: 67-77.
110. Palomaki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett 1997; 410:254-8.
111. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 Suppl: S137-44.
112. de Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R. Effects of lipid-lowering chugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473-8.
113. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999; 49: 324-9.
114. Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001; 142: E2.
115. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas K Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287: 598-605.
116. Passi S, Stancato A, Aleo, E, Dmitrieva A, Littaru GP. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003; 18: 113-24.
117. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004; 94: 1306-10.
118. Rundek T, Naini A, Sacco R, Coates Y, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004; 61: 889-92.
119. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005; 179: 201-6.
120. Colquhoun DM, Jackson R, Walters M, et al. Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans. Eur J Clin Invest 2005; 35: 251-8.
121. Willis RA, Folkers Y, Tucker JL, Ye CQ, Xia LJ, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990; 87: 8928-30.
122. Belichard P, Praneau D, Zhiri A. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochim Biophys Acta 1993; 1169: 98-102.
123. Fukami M, Maeda N, Fukushige J, et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 1993; 193: 263-73.
124. Diebold BA, Bhagavan NV, Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim, Biophys Acta 1994; 1200: 100-8.
125. Loop RA, Anthony M, Willis RA, Folkers K. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. Mol Aspects Med 1994; 15 Suppl: s195-206.
126. Satoh Y, Yamato A, Nakai T, Hoshi K, Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mithochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995; 116:1894-8.
127. Morand OH, Aebi JD, Dehmlow H, et al. Ro 48-8.071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res 1997; 38: 373-90.
128. Nakahara K, Kuriyama M, Sonoda Y, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electro-physiological, and biochemical study. Toxicol Appl Pharmacol 1998; 152: 99-106.
129. Palomaki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998; 39: 1430-7.
130. Hiyoshi H, Yanagimachi M, Ito M, et al. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol 2001; 431: 345-52.
131. Ugawa T, Kakuta H, Moritani H, Inagaki O. Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br J Pharmacol 2002; 137: 561-9.
132. Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, Sugiyama Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 2003; 466: 155-61.
133. Goto S, Shimokawa T, Ugawa T, et al. Species specificity in the blood cholesterol-lowering effect of YM-16638. Br J Pharmacol 1996; 118:174-8.
134. Ishihara T, Kakuta H, Moritani H, Ugawa T, Yanagisawa I. Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors. Chem Pharm Bull (Tokyo) 2004; 52: 1204-9.